Metagenomi Therapeutics (MGX) Depreciation & Amortization (CF) (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $1.3 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $1.3 million, down 6.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (down 4.89% YoY), and the FY2025 annual result was $5.3 million, down 1.85% from the prior year.
• Depreciation & Amortization (CF) declined to $1.3 million in Q1 2026 per MGX's latest filing, from $1.3 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.5 million in Q4 2024 and troughed at $841000.0 in Q1 2023.
• A 4-year average of $1.2 million and a median of $1.3 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) jumped 51.37% in 2024, then slipped 11.76% in 2025.
• A 4-year view of Depreciation & Amortization (CF) shows it stood at $1.2 million in 2023, then gained by 21.78% to $1.5 million in 2024, then fell by 11.76% to $1.3 million in 2025, then fell by 0.62% to $1.3 million in 2026.
• Business Quant data shows MGX's Depreciation & Amortization (CF) at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.